Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc is positioned favorably due to its ongoing development of targeted therapies, specifically in addressing oncogenic mutations, with products like BDTX-4933 and BDTX-1535 in its pipeline. Positive outcomes in objective response rates (ORR) anticipated in the second half of 2025 could lead to projected sales of approximately $500-750 million, reflecting a strong market potential. Furthermore, valuations for similar oncology acquisitions suggest that the company could experience substantial upside, estimated at 3-6 times its current valuation, based on M&A proxy data.

Bears say

The negative outlook on Black Diamond Therapeutics Inc. is primarily driven by significant risks associated with its clinical trials, specifically the potential for disappointing efficacy and safety outcomes for its lead candidate, Silevertinib. Additionally, unforeseen delays in research and development, as well as regulatory or commercial challenges, may hinder the company's progress and operational viability. The competitive landscape in the non-classical EGFR mutation non-small cell lung cancer space further exacerbates these concerns, alongside the critical need for sufficient capital to fund ongoing research initiatives.

BDTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, BDTX has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.